AMSPARITY Trademark

Trademark Overview

On Friday, May 8, 2020, a trademark application was filed for AMSPARITY with the United States Patent and Trademark Office. The USPTO has given the AMSPARITY trademark a serial number of 88907939. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 1, 2024. This trademark is owned by Pfizer Inc.. The AMSPARITY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
amsparity

General Information

Serial Number88907939
Word MarkAMSPARITY
Filing DateFriday, May 8, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 6, 2020

Trademark Statements

Description of MarkThe mark consists of the following: An orange vertical bar on the left of the literal element "Amsparity" depicted in the color black.
Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
Indication of Colors claimedThe color(s) orange and black are claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 21, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Tuesday, January 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 1, 2024ABANDONMENT - NO USE STATEMENT FILED
Friday, May 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 4, 2023SOU EXTENSION 5 GRANTED
Monday, May 1, 2023SOU EXTENSION 5 FILED
Thursday, May 4, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, May 1, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, March 28, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 28, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 28, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, November 19, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 17, 2022SOU EXTENSION 4 GRANTED
Thursday, November 17, 2022SOU EXTENSION 4 FILED
Thursday, November 17, 2022SOU TEAS EXTENSION RECEIVED
Saturday, May 14, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 12, 2022SOU EXTENSION 3 GRANTED
Thursday, May 12, 2022SOU EXTENSION 3 FILED
Thursday, May 12, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, November 17, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 15, 2021SOU EXTENSION 2 GRANTED
Monday, November 15, 2021SOU EXTENSION 2 FILED
Monday, November 15, 2021SOU TEAS EXTENSION RECEIVED
Saturday, May 22, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 20, 2021SOU EXTENSION 1 GRANTED
Thursday, May 20, 2021SOU EXTENSION 1 FILED
Thursday, May 20, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, December 1, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 6, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 6, 2020PUBLISHED FOR OPPOSITION
Wednesday, September 16, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sunday, August 30, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 7, 2020EXAMINER'S AMENDMENT ENTERED
Friday, August 7, 2020ASSIGNED TO LIE
Friday, August 7, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, August 7, 2020EXAMINERS AMENDMENT E-MAILED
Friday, August 7, 2020EXAMINERS AMENDMENT -WRITTEN
Wednesday, July 29, 2020ASSIGNED TO EXAMINER
Friday, May 22, 2020NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, May 21, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 12, 2020NEW APPLICATION ENTERED

Related Keywords

amsparity preparations disorders pharmaceutical treatment hypertension pain stroke cancer growth bone